welcome back to the party...
Sentiment: Strong Buy
thy were neutral before . i wonder what their target was. mine is 150 by end of year
Pharmacyclics upgraded to Buy from Neutral at Lazard Capital
Lazard Capital upgraded Pharmacyclics with a $141 price target citing the growth potential of the company's cancer drug ibrutinib. This is just getting started folks.